Literature DB >> 3954724

The acceleration of the inhibition of platelet prothrombinase complex by heparin.

V Ellis, M F Scully, V V Kakkar.   

Abstract

The influence of heparin on the inhibition of factor Xa has been studied under conditions where factor Xa is bound to collagen-thrombin-stimulated platelets to form the prothrombinase complex. Unfractionated heparin was found to cause a concentration-dependent acceleration of the inhibition of the platelet prothrombinase complex up to a maximum rate constant of 4.1 X 10(7) M-1 X min-1 at heparin concentrations of 0.2 microM and above. This is equivalent to a 4800-fold acceleration over the rate constant for the inhibition in the absence of heparin, and is 6.8-fold lower than the rate constant for the inhibition of uncomplexed factor Xa in the presence of saturating concentrations of heparin which was determined as 2.8 X 10(8) M-1 X min-1. The effects of three Mr fractions of heparin were also studied. These were a gel-filtered heparin of Mr 15000, a gel-filtered heparin of Mr 6000 and a heparin oligosaccharide (primarily 8-10 monosaccharide units) prepared by nitrous acid depolymerization, each with high affinity for antithrombin III. These fractions all accelerated the rate of the antithrombin III inhibition of the platelet prothrombinase complex, with maximum rate constants of 6.8 X 10(7), 1.4 X 10(7) and 9.8 X 10(6) M-1 X min-1, respectively. On comparison with the effect of these heparin fractions on the rate of inhibition of uncomplexed factor Xa a progressively increasing disparity between the rate of inhibition of uncomplexed and complexed factor Xa was observed, rising from 1.7-fold with the oligosaccharide to 6.8-fold with the unfractionated heparin. A possible mechanism for this differential activity between uncomplexed and complexed factor Xa with the various heparin fractions is discussed in terms of an involvement of heparin binding to factor Xa.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954724      PMCID: PMC1152998          DOI: 10.1042/bj2330161

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

1.  Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase.

Authors:  R KITZ; I B WILSON
Journal:  J Biol Chem       Date:  1962-10       Impact factor: 5.157

2.  On the molecular-weight-dependence of the anticoagulant activity of heparin.

Authors:  L Thunberg; U Lindahl; A Tengblad; T C Laurent; C M Jackson
Journal:  Biochem J       Date:  1979-07-01       Impact factor: 3.857

3.  Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma.

Authors:  L O Andersson; T W Barrowcliffe; E Holmer; E A Johnson; G Söderström
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

4.  Studies on the formation of the prothrombin-converting complex.

Authors:  F Jobin; M P Esnouf
Journal:  Biochem J       Date:  1967-03       Impact factor: 3.857

5.  Properties of the factor Xa binding site on human platelets.

Authors:  J P Miletich; C M Jackson; P W Majerus
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

6.  The effect of divalent metal cations on the inhibition of human coagulation factor Xa by plasma proteinase inhibitors.

Authors:  V Ellis; M Scully; V Kakkar
Journal:  Biochim Biophys Acta       Date:  1983-09-14

7.  The binding of low molecular weight heparin to hemostatic enzymes.

Authors:  R E Jordan; G M Oosta; W T Gardner; R D Rosenberg
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

8.  The role of phospholipids and factor Va in the prothrombinase complex.

Authors:  J Rosing; G Tans; J W Govers-Riemslag; R F Zwaal; H C Hemker
Journal:  J Biol Chem       Date:  1980-01-10       Impact factor: 5.157

9.  Inhibition of prothrombinase complex by plasma proteinase inhibitors.

Authors:  V Ellis; M F Scully; V V Kakkar
Journal:  Biochemistry       Date:  1984-11-20       Impact factor: 3.162

10.  Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.

Authors:  V V Kakkar; B Djazaeri; J Fok; M Fletcher; M F Scully; J Westwick
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-06
View more
  5 in total

1.  Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.

Authors:  Ivan Stevic; Howard H W Chan; Leslie R Berry; Ankush Chander; Anthony K C Chan
Journal:  J Biochem       Date:  2012-10-24       Impact factor: 3.387

2.  Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor.

Authors:  J Franssen; I Salemink; G M Willems; T C Wun; H C Hemker; T Lindhout
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

3.  The relative molecular mass dependence of the anti-factor Xa properties of heparin.

Authors:  V Ellis; M F Scully; V V Kakkar
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

4.  The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.

Authors:  T W Barrowcliffe; S J Havercroft; G Kemball-Cook; U Lindahl
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

5.  Establishing the Transient Mass Balance of Thrombosis: From Tissue Factor to Thrombin to Fibrin Under Venous Flow.

Authors:  Shu Zhu; Jason Chen; Scott L Diamond
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05-03       Impact factor: 8.311

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.